Vice President, Market Access
Immunic Therapeutics
Vice President, Market Access
Immunic Therapeutics
Clinical-stage biopharma developing oral autoimmune therapies
Summary
We are seeking an accomplished and entrepreneurial Vice President, Market Access to build and lead the company's U.S. Market Access organization as we prepare for the anticipated launch of vidofludimus calcium for the treatment of relapsing multiple sclerosis (RMS). The ideal candidate brings deep experience in the multiple sclerosis marketplace, established relationships across national and regional payers, specialty pharmacies, and key health systems, and a proven track record of building high-performing Market Access organizations in preparation for launch.
You must be a highly strategic leader who has successfully led one or more multiple sclerosis product launches and understands how payer strategy, pricing, reimbursement, contracting, distribution, and field market access capabilities work together to maximize patient access and commercial success. As a member of the Commercial Leadership Team, you will help shape Immunic's overall commercialization strategy while building a best-in-class Market Access organization capable of supporting long-term commercial growth.
Responsibilities
Lead U.S. Market Access strategy and organization build for vidofludimus calcium's launch, covering pricing, contracting, reimbursement, and distribution
Develop integrated access strategies spanning Commercial, Medicare, Medicaid, VA, DoD, and other government channels
Own national payer strategy, negotiating with health plans, PBMs, IDNs, health systems, and specialty pharmacies
Build payer value propositions using clinical, economic, and real-world evidence to drive favorable formulary coverage
Set pricing strategy, gross-to-net assumptions, and specialty pharmacy/trade/distribution frameworks, ensuring launch-ready operations
Partner with Medical Affairs/HEOR on payer evidence strategy, AMCP dossiers, and value communication; support post-launch evidence generation
Serve on Commercial Leadership Team, coordinating with Marketing, Sales, Medical, Regulatory, Finance, Legal, and Supply Chain on launch readiness
Design and build the Market Access org structure, capabilities, and metrics across Payer Strategy, Marketing, Pricing/Contracting, Trade, Analytics, and Excellence functions
Recruit and lead a field Market Access team: National, Federal, and Regional Account Managers plus Field Reimbursement Managers
Set field deployment strategy (territories, hiring, training, incentives) and ensure tight collaboration with Sales and Medical Affairs to maximize adoption
Qualifications & Education
Bachelor's degree required; MBA, PharmD, MPH, or other advanced degree preferred.
15+ years of progressive leadership experience within the pharmaceutical or biotechnology industry.
Demonstrated success leading U.S. Market Access organizations for specialty pharmaceutical products.
Direct experience leading the U.S. Market Access strategy for one or more multiple sclerosis product launches is strongly preferred.
Candidates who have played a significant leadership role in the commercialization of successful MS therapies will be strongly favored.
Deep understanding of the competitive dynamics, payer landscape, specialty pharmacy networks, treatment centers, and reimbursement environment within multiple sclerosis as well as negotiating with commercial payers, PBMs, Medicare Part D plans, federal healthcare systems, specialty pharmacies, and integrated health systems.
Demonstrated success building and leading field-based Market Access organizations; experience building commercial infrastructure within an emerging biotechnology company or first-launch organization strongly preferred.
Immunic Therapeutics is an Equal Opportunity Employer. We are committed to fostering a diverse, inclusive, and equitable workplace where all individuals are valued and respected. Employment decisions are based on qualifications, merit, and business needs, without regard to race, color, religion, gender, sexual orientation, national origin, disability, veteran status, or any other protected status.
Please note, Immunic does not accept unsolicited resumes from external agencies or recruiters. Submission of a resume without a prior written agreement does not create any express or implied contract between Immunic and the agency. Immunic will not pay any fees related to unsolicited resumes.
Clinical-stage biopharma developing oral autoimmune therapies
Immunic Therapeutics develops oral therapies for chronic inflammatory and autoimmune diseases and is in clinical-stage development. Its lead candidate, vidofludimus calcium (IMU-838), is an oral small molecule that activates the Nurr1 receptor to protect nerve cells and inhibits DHODH to calm overactive immune responses; its pipeline also includes IMU-856, a SIRT6 modulator aimed at restoring intestinal barrier function, with IMU-381 in preclinical GI programs. The company emphasizes oral, small-molecule drugs with dual actions and pursues partnerships or licensing for commercialization rather than relying on near-term product revenue. Its goal is to advance its drug candidates through clinical trials toward commercialization, potentially via collaborations with larger pharma companies.
Explore more opportunities at Immunic Therapeutics